Cartesian Therapeutics, Inc. Common Stock
RNACCartesian Therapeutics, Inc. (RNAC) focuses on developing cell-based immunotherapies to treat various diseases. The company leverages its proprietary platform to engineer natural killer (NK) cells and other immune cells for targeted therapeutic applications, aiming to provide precise and effective treatments with minimal side effects.
Company News
Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibi...
Cartesian Therapeutics secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending cash runway into 2028. The company expects Phase 3 AURORA trial topline data for Descartes-08 in myasthenia gravis in Q1 2027, with BLA filing planned for mid-2027. Additional clinical data from Phase 2...
The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB...
Cartesian Therapeutics announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company, a late clinical-stage biotech firm, is advancing its lead asset Descartes-08, a CAR-T cell therapy in Phase 3 development for generalized myasthenia gravis and Phase 2 for myositis, with Phase 1/2 trial...
The generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, B...
